Dr. Suh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
304 Randall Rd
Geneva, IL 60134Phone+1 630-232-0610Fax+1 630-232-0675
Education & Training
The University of Chicago Booth School of BusinessMBA, Business Administration, 2018 - 2020
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Yale-New Haven Medical CenterResidency, Internal Medicine, 2004 - 2006
University of Pennsylvania Health SystemInternship, Internal Medicine, 2003 - 2004
Yale School of MedicineClass of 2003- Yale UniversityBS, Molecular Biophysics and Biochemistry, Distinction in Major, 1995 - 1999
Certifications & Licensure
IL State Medical License 2012 - 2026
IN State Medical License 2010 - 2013
TX State Medical License 2007 - 2012
CT State Medical License 2006 - 2008
PA State Medical License 2003 - 2004- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Oncologist Consumer Research Council of America
- Young Investigator Award American Society of Clinical Oncology
- Fellowship in Translational Research American Association for Cancer Research
Publications & Presentations
PubMed
- 26 citationsA UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.Manish R. Sharma, Smita S. Joshi, Theodore Karrison, Kenisha Allen, Grace K. Suh
Cancer. 2019-05-15 - 2 citationsProspective Evaluation of Circulating Tumor DNA using Next Generation Sequencing as a Biomarker during Neoadjuvant Chemotherapy in Localized Pancreatic Cancer.Dhavan Shah, Amy Wells, Madison Cox, Kevin Dawravoo, John Abad
Annals of Surgery. 2024-01-23 - 49 citationsARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenograftsMichele N. Washington, Grace Suh, Aaron F. Orozco, Margie N. Sutton, Hailing Yang
Cell Death & Disease. 2015-08-06
Press Mentions
What to Know About Living with Multiple Myeloma at a Young AgeJanuary 17th, 2024
Professional Memberships
- Member
- Member
Other Languages
- Korean
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
